Cybin CEO to Discuss Psychedelic Therapeutics at Virtual Healthcare Showcase

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company, announced that its CEO, Doug Drysdale, will engage in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase on May 21, 2025. This session, webcast live at 1:40 p.m. ET, will later be accessible through the company's investor relations site. Cybin is at the forefront of developing psychedelic-based therapeutics aimed at addressing the significant unmet needs in mental health treatment.

The company's mission revolves around creating safe and effective treatments for mental health conditions, leveraging a network of esteemed partners and scientists. Cybin's current projects include CYB003, a deuterated psilocybin analog for major depressive disorder, and CYB004, a deuterated DMT molecule for generalized anxiety disorder, alongside a pipeline of investigational psychedelic compounds. Founded in 2019 and headquartered in Canada, Cybin operates across several countries, including the United States, the United Kingdom, the Netherlands, and Ireland.

This event underscores the growing interest and investment in psychedelic therapeutics as a viable solution to mental health challenges. Cybin's participation in the showcase not only highlights its contributions to the field but also signals the potential for psychedelic-based treatments to revolutionize mental healthcare. The implications of such advancements could lead to more effective treatment options for individuals suffering from mental health conditions, marking a significant step forward in the industry.